Once more: prevention of nausea and emesis in cancer treatment

✍ Scribed by M. S. Aapro

• Book ID: 104766822
• Publisher: Springer-Verlag
• Year: 1994
• Tongue: English
• Weight: 124 KB
• Volume: 2
• Category: Article
• ISSN: 0941-4355
• DOI: 10.1007/bf00417470

✦ Synopsis

Once more: prevention of nausea and emesis in cancer treatment

Readers of Supportive Care in Cancer will certainly not be surprised to find a series of papers on cancer-treatment-related nausea and vomiting in this issue. But what is the reason for our continued interest for this field? The advent of the serotonin type-3 (5-HT3) receptor antagonists led to considerable progress, nicely summarised in the paper of Tonato et al., a leading group in the field. However, these new agents have not solved the problem, as one is more and more aware of our shortcomings in the prevention of delayed emesis, where the role, if any, of these agents has yet to be proven [1,2]. Tonato et al. have considerable experience with old and new antiemetics; their paper reflects their involvement in key studies with ondansetron, and they have certainly demonstrated the superiority of the combination of ondansetron and dexamethasone over the previous "gold standard" based on metoclopramide, as discussed in another paper in this is-